FOLR1 and ovarian carcinoma: The ADC therapeutic field is rapidly expanding, with >20 ongoing trials across gynecologic malignancies, including phase III (NCT04296890) of MIRV in FRα-high platinum-resistant ovarian cancers (49, 50).